Panitumumab, Federal Administrative Court (Bundesverwaltungsgericht),18 August 2011
January 13, 2012
An SPC can only be granted if the product falls within the scope of protection of the basic patent. If the basic patent claims a combination of two known components (i.e. a monoclonal antibody with a neoplastic agent), that combination is the patent's contribution to the art. An individual component is not equivalent to the patented combination and does not fall within the scope of protection of the basic patent.
Click here for the full text of this case. A summary of this case will be posted on http://www.KluwerIPCases.com.
Comments (0)
Your email address will not be published.
Become a contributor!
Interested in contributing? Submit your proposal for a blog post now and become a part of our legal community!
Contact Editorial Guidelines
